|
SPRB
|
|
$0.07
* Data may be delayed
|
|
|
COMPANY INFORMATION
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.. |
INCOME
Calendar Year2024Revenue4.91m Cost of Revenue0 Gross Profit4.91m Gross Profit Ratio1 |
|
|
Sponsored By: Benzinga 103806 People Checked This Out
How To Hit More Winning Option Trades
Dear Reader,
There's nothing worse for a new options trader than to…
Guess which option trades to enter.
Do a bunch of work and still make the wrong picks.
And end up wasting a ton of time with little to no gains.
But that doesn't have to happen to you.
Now you can join Options Starter and get 75% off.
Picked for you by Nic Chahine.
The Head of Options Trading at Benzinga.
Who has one of the best track records we know of…
Including recent winning trades like:
90% ROI on JD
511% ROI on AXP
66% ROI on BX
As a member of Options Starter you get:
2 hand-picked option trades per month
Real-time email or SMS entry & exit alerts
Plus a BONUS intro series on option trading
For up to 75% off!
Click Here To Get 75% Off Today!
|
